重组人表皮生长因子联合光子嫩肤M22对痤疮凹陷性瘢痕患者皮肤屏障功能的影响

摘要 目的：探讨与分析重组人表皮生长因子联合光子嫩肤M22对痤疮凹陷性瘢痕患者皮肤屏障功能的影响。方法：2020年9月到2022年2月选择在本院诊治的痤疮凹陷性瘢痕患者120例作为研究对象，根据1:1简单分配原则把患者分为联合组与对照组各60例。对照组给予重组人表皮生长因子治疗，联合组在对照组治疗的基础上给予光子嫩肤M22治疗，两组都治疗观察4周。结果：治疗后联合组的总有效率为88.3 %，高于对照组的66.7 %（P<0.05）。联合组的红斑消退时间等临床症状较对照组少（P<0.05）。两组治疗后皮肤油脂比例低于治疗前，皮肤含量水高于治疗前，治疗后联合组的皮肤油脂比例、含水量与对照组对比有差异（P<0.05）。两组治疗后的瘢痕基底深度较治疗前低，联合组较对照组低（P<0.05）。治疗后，两组主观、客观美学评分较治疗前高，联合组较对照组高（P<0.05）。结论：重组人表皮生长因子联合光子嫩肤M22在痤疮凹陷性瘢痕患者的能改善皮肤屏障功能，能降低瘢痕基底深度与皮肤油脂比例，提高皮肤含水量，能促进改善临床症状，提高皮肤的美学评分，从而提高总体治疗效果。

Effects of Recombinant Human Epidermal Growth Factor Combined with Photorejuvenation M22 on Skin Barrier Function in Patients with Acne Pitting Scars

ABSTRACT Objective: To explore and analysisi the effects of recombinant human epidermal growth factor combined with photorejuvenation M22 on skin barrier function in patients with acne pitted scars. Methods: From September 2020 to February 2022, 120 cases of patients with acne pitting scars who were diagnosed and treated in our hospital were selected as the research subjects. All the cases were divided into the combination group and the control group with 60 cases in each group, accorded to the simple allocation principle of 1:1. The control group were treated with recombinant human epidermal growth factor, and the combination group were treated with photorejuvenation M22 based on the treatment of the control group. Both groups were treated and observed for 4 weeks. Results: After treatment, the total effective rates of the combination group were 88.3 %, which were higher than 66.7 % of the control group (P<0.05). The combined group had fewer clinical symptoms such as erythema regression time than the control group (P<0.05). After treatment, the proportion of skin oil in the two groups were lower than that before treatment, and the water content in the skin were higher than that before treatment (P<0.05). The depth of scar base after treatment in the two groups were significantly lower than that before treatment, and the combination group were significantly lower than that in the control group (P<0.05). The subjective and objective aesthetic scores of the two groups after treatment were higher than those before treatment, and the combination group were higher than that of the control group (P<0.05). Conclusion: Recombinant human epidermal growth factor combined with photorejuvenation M22 can improve skin barrier function in patients with acne pitting scar, can reduce the depth of scar base and the ratio of skin oil, increase skin water content, can promote the improvement of clinical symptoms, and improve skin aesthetics score, thereby improving the overall treatment effect.